BR112014008412A2 - derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral - Google Patents

derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral

Info

Publication number
BR112014008412A2
BR112014008412A2 BR112014008412A BR112014008412A BR112014008412A2 BR 112014008412 A2 BR112014008412 A2 BR 112014008412A2 BR 112014008412 A BR112014008412 A BR 112014008412A BR 112014008412 A BR112014008412 A BR 112014008412A BR 112014008412 A2 BR112014008412 A2 BR 112014008412A2
Authority
BR
Brazil
Prior art keywords
viral disease
pyrimidin
derivatives
amelioration
prevention
Prior art date
Application number
BR112014008412A
Other languages
English (en)
Portuguese (pt)
Inventor
Wolkerstorfer Andrea
Giethlen Bruno
Morice Christophe
Michaut-Simon Céline
Classen-Houben Dirk
Jung Laurence
Smith Mark
Szolar Oliver
Cusack Stephen
So Sung-Sau
Langer Thierry
Original Assignee
European Molecular Biology Laboratory
Hoffmann La Roche
Savira Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Molecular Biology Laboratory, Hoffmann La Roche, Savira Pharmaceuticals Gmbh filed Critical European Molecular Biology Laboratory
Publication of BR112014008412A2 publication Critical patent/BR112014008412A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014008412A 2011-10-21 2012-10-19 derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral BR112014008412A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550057P 2011-10-21 2011-10-21
PCT/EP2012/070760 WO2013057253A1 (en) 2011-10-21 2012-10-19 Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
BR112014008412A2 true BR112014008412A2 (pt) 2017-04-11

Family

ID=47189887

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008412A BR112014008412A2 (pt) 2011-10-21 2012-10-19 derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral

Country Status (11)

Country Link
US (2) US20130102601A1 (https=)
EP (1) EP2794616B1 (https=)
JP (1) JP6033873B2 (https=)
KR (1) KR20140097197A (https=)
CN (1) CN103958521B (https=)
BR (1) BR112014008412A2 (https=)
CA (1) CA2852843A1 (https=)
ES (1) ES2589459T3 (https=)
MX (1) MX342176B (https=)
RU (1) RU2014120477A (https=)
WO (1) WO2013057253A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074880A (zh) 2014-07-07 2017-08-18 萨维拉制药有限公司 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
WO2016033150A1 (en) * 2014-08-28 2016-03-03 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof
WO2016133888A1 (en) * 2015-02-16 2016-08-25 Biota Pharmaceuticals, Inc. Compounds for treating respiratory syncytial virus infections
SG11201708721XA (en) 2015-04-28 2017-11-29 Shionogi & Co Substituted polycyclic pyridone derivative and prodrug thereof
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
SG11201804348SA (en) * 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2018001948A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Pyridazinone-based broad spectrum anti-influenza inhibitors
KR20190018469A (ko) 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
AU2018312349A1 (en) 2017-08-01 2020-02-06 Theravance Biopharma R&D Ip, Llc Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
KR20230005210A (ko) * 2020-04-08 2023-01-09 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
CN116997555A (zh) * 2021-03-17 2023-11-03 豪夫迈·罗氏有限公司 新颖噻吩并嘧啶酮衍生物
US11932656B1 (en) 2023-10-06 2024-03-19 King Faisal University Thieno[2,3-d]pyrimidines as COX-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
ES2314224T3 (es) * 2002-03-07 2009-03-16 F. Hoffmann-La Roche Ag Inhibidores pirimidina y piridina biciclicos de p38 quinasa.
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
EP2215094B1 (en) * 2007-11-15 2016-01-27 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
WO2010103130A2 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Also Published As

Publication number Publication date
WO2013057253A1 (en) 2013-04-25
HK1199881A1 (en) 2015-07-24
CA2852843A1 (en) 2013-04-25
CN103958521B (zh) 2016-10-19
MX342176B (es) 2016-09-20
JP6033873B2 (ja) 2016-11-30
KR20140097197A (ko) 2014-08-06
CN103958521A (zh) 2014-07-30
EP2794616B1 (en) 2016-06-29
RU2014120477A (ru) 2015-11-27
US20160376286A1 (en) 2016-12-29
MX2014003801A (es) 2015-03-11
JP2014530838A (ja) 2014-11-20
EP2794616A1 (en) 2014-10-29
US20130102601A1 (en) 2013-04-25
ES2589459T3 (es) 2016-11-14

Similar Documents

Publication Publication Date Title
BR112014008412A2 (pt) derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
BR112014029006A2 (pt) derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
BR112014001369A2 (pt) derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral
HK1211289A1 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
MX2009011755A (es) Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
ATE517882T1 (de) Chinolinderivate
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012048129A3 (en) Inhibitors of polo-like kinase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.